Cost‐effectiveness of finerenone added to standard of care for patients with type 2 diabetes‐related chronic kidney disease in the United States
Authors' conclusion
For patients with T2DM-related CKD, adding finerenone to SoC may be a cost-effective option in the United States. Reasonable price reductions for finerenone could potentially benefit more patients.
Study context
- Population
- Patients with T2D-related chronic kidney disease (CKD) in the United States; clinical data from FIDELITY
- Comparison
- Standard of care (SoC) + finerenone vs SoC
- Outcome
- Incremental cost-effectiveness ratio (ICER) and QALYs
- Follow-up
- 35 years
Methodological detailsMarkov model, FINE-CKD model, US payer perspective, 35-year horizon, 4-month cycles, deterministic and probabilistic sensitivity analyses
- Markov model
- FINE-CKD model
- US payer perspective
- 35-year horizon, 4-month cycles
- Deterministic and probabilistic sensitivity analyses
Main finding
As reported in the abstract
QALYs, lifetime cost and ICER · 35-year horizon
Incremental quality-adjusted life years (QALYs)
0.48 QALYs
more with SoC + finerenone
Added cost
65 305.72 $
higher with SoC + finerenone
SoC + finerenone
6.95
QALYs
- Incremental cost-effectiveness ratio (ICER) for finerenone, below US willingness-to-pay threshold ($150 000/QALY)
- $135 257.06 per QALY
Further findings
Sensitivity analyses
- Probability SoC + finerenone cost-effective (probabilistic sensitivity analysis)
- 57.6%
- Results sensitive to HRs for finerenone efficacy and its cost
Original publication
Cost‐effectiveness of finerenone added to standard of care for patients with type 2 diabetes‐related chronic kidney disease in the United States. Diabetes Obes Metab. Published 8 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →